MetaVia Inc.

NasdaqCM:MTVA Stock Report

Market Cap: US$6.1m

MetaVia Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Hyung Heon Kim

Chief executive officer

US$756.3k

Total compensation

CEO salary percentage63.43%
CEO tenure2.8yrs
CEO ownershipn/a
Management average tenure2.8yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

Analysis Article • Sep 17

We're Keeping An Eye On MetaVia's (NASDAQ:MTVA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 03

Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Sep 29

NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

NeuroBo Pharmaceuticals (NASDAQ:NRBO) received Nasdaq notification indicating that the company has evidenced full compliance with the minimum bid price requirement As a result, the listing matter has been closed. Shares are trading up 4% premarket.
Analysis Article • Sep 14

Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Sep 12

NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split

NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares are surging 56% on announcing a 1-for-30 reverse split of its common stock, par value $0.001.  The trading on a split adjusted basis will commence on Nasdaq from September 13, 2022. The number of authorized shares of the company's common stock will remain at 100M, while the number of outstanding shares will be reduced from ~26.7M to ~0.9M.
Seeking Alpha • Nov 25

NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases

NeuroBo Pharmaceuticals is advancing novel disease-modifying therapies for viral, neuropathic and neurodegenerative diseases. The Company has four candidates in the development pipeline, with the lead candidate ANA001 being advanced for treatment of moderate COVID-19. The Company seeks an EUA for the lead candidate, failing which it intends to pursue an NDA via a 505(b)(2) pathway.
Analysis Article • Dec 21

Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like

If you want to know who really controls NeuroBo Pharmaceuticals, Inc. ( NASDAQ:NRBO ), then you'll have to look at the...

CEO Compensation Analysis

How has Hyung Heon Kim's remuneration changed compared to MetaVia's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$756kUS$480k

-US$13m

Sep 30 2025n/an/a

-US$16m

Jun 30 2025n/an/a

-US$18m

Mar 31 2025n/an/a

-US$25m

Dec 31 2024US$716kUS$460k

-US$28m

Sep 30 2024n/an/a

-US$28m

Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$17m

Dec 31 2023US$1mUS$174k

-US$12m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$11m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$61kn/a

-US$14m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$14m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$29kn/a

-US$15m

Compensation vs Market: Hyung Heon's total compensation ($USD756.33K) is about average for companies of similar size in the US market ($USD627.70K).

Compensation vs Earnings: Hyung Heon's compensation has increased whilst the company is unprofitable.

CEO

Hyung Heon Kim (48 yo)

2.8yrs
Tenure
US$756,328
Compensation

Mr. Hyung Heon Kim had been Independent Director of MetaVia Inc. (formerly known as NeuroBo Pharmaceuticals, Inc.) since July 09, 2021 until August 11, 2023 and serves as its Chief Executive Officer, Presi...

Leadership Team

NamePositionTenureCompensationOwnership
Hyung Heon Kim
CEO, President & Director2.8yrsUS$756.33kno data
Marshall Woodworth
Chief Financial Officer2.6yrsUS$562.99k0.012%
$ 716.6
Mi-Kyung Kim
Chief Scientific Officer2.8yrsno datano data
Robert Homolka
Senior Vice President of Clinical Operations2.8yrsno datano data
W. Fang
Consulting Chief Medical Officer & Advisorno datano datano data
Michael Pine
Senior Vice President of Business Development Advisor1.3yrsno datano data
2.8yrs
Average Tenure
48yo
Average Age

Experienced Management: MTVA's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Hyung Heon Kim
CEO, President & Director4.8yrsUS$756.33kno data
D. Strickland
Independent Director4.3yrsUS$82.10k0.031%
$ 1.9k
Andrew Koven
Independent Chairman of the Board4.8yrsUS$112.10k0%
$ 0
Michael Salsbury
Independent Director6.4yrsUS$70.10k0.017%
$ 1.1k
Roy Freeman
Chairman of Scientific Advisory Boardno datano datano data
Mark Glickman
Independent Director3yrsUS$73.10k0.017%
$ 1.1k
Jason Groves
Independent Director6.4yrsUS$63.10k0.017%
$ 1.1k
James Tursi
Independent Director2.5yrsUS$63.10k0.015%
$ 896.0
Carel Le Roux
Member of Scientific Advisory Boardno datano datano data
Angela Fitch
Member of Scientific Advisory Boardno datano datano data
Lee Kaplan
Member of Scientific Advisory Boardno datano datano data
4.8yrs
Average Tenure
63.5yo
Average Age

Experienced Board: MTVA's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/15 21:56
End of Day Share Price 2026/05/15 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MetaVia Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew FeinH.C. Wainwright & Co.
Jason McCarthyMaxim Group
David BautzZacks Small-Cap Research